文献速递肺结节与肺癌

胸水游离DNA对肺腺癌致癌突变诊断产出高

High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma.
PubMed 文献 · Chest · 2023-01-21

该前瞻性研究纳入2017年1月至2021年9月42例肺腺癌恶性胸腔积液患者,比较胸水cfDNA、胸水细胞学、活检和血浆cfDNA检测致癌突变的诊断产出分别为90.7%、48.5%、88%和75%(P<.001)。胸水cfDNA与细胞学阳性样本突变一致率100%,与活检一致率89.4%,提示胸水cfDNA NGS可作为评估致癌突变的可靠方法。

要点

  • 胸水cfDNA NGS检测致癌突变产出达90.7%,与活检相当且高于细胞学和血浆cfDNA。
  • 胸水cfDNA与细胞学阳性样本突变一致率100%,与活检一致率89.4%。
  • 中位5 mL胸水上清即可满足cfDNA检测,且可纵向采集。

核心结论

  • 肺腺癌恶性胸腔积液患者中,胸水cfDNA NGS检测致癌突变的诊断产出与肿瘤活检相当,高于胸水细胞学和血浆cfDNA。

研究设计与样本

  • 前瞻性研究,2017年1月至2021年9月招募肺腺癌恶性胸腔积液患者,共收集42例患者的54份胸水样本。

主要发现

  • 胸水cfDNA、胸水细胞学、活检和血浆cfDNA检测致癌突变的诊断产出分别为49/54(90.7%)、16/33(48.5%)、22/25(88%)和24/32(75%),P < .001。
  • 胸水cfDNA与胸水细胞学阳性样本的突变一致率为100%,与活检的一致率为89.4%。
  • 胸水cfDNA中位浓度(四分位距)为28,444(4,957-67,051)个可扩增DNA拷贝/mL,高于血浆的2,966.5(2,167-5,025)拷贝/mL,P < .01。
  • 胸水中位5 mL(四分位距4.5-5)上清足以进行cfDNA检测。

临床怎么用

  • 胸水cfDNA可纵向采集并易于融入临床工作流程,可能减少额外活检的需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pleural cytology is currently used to assess targetable mutations in patients with advanced lung adenocarcinoma. However, it is fraught with low diagnostic yield. RESEARCH QUESTION: Can pleural cell-free DNA (cfDNA) be used to assess targetable mutations in lung adenocarcinoma patients with malignant pleural effusions (MPE)? STUDY DESIGN AND METHODS: Patients with lung adenocarcinoma MPE were recruited prospectively between January 2017 and September 2021. Oncogenic mutations were assessed by treating providers using pleural fluid cytology or lung cancer biopsies. Pleural and plasma cfDNA were used to assess the mutations using next-generation sequencing (NGS). RESULTS: Fifty-four pleural fluid samples were collected from 42 patients. The diagnostic yield to detect oncogenic mutations for pleural cfDNA, pleural cytology, biopsy, and plasma cfDNA was 49/54 (90.7%), 16/33 (48.5%), 22/25 (88%), and 24/32 (75%), respectively, P < .001. The agreement of mutations in positive samples between pleural cfDNA and pleural cytology was 100%, whereas the agreement of pleural cfDNA with biopsies was 89.4%. The median concentration (interquartile range) of pleural cfDNA was higher than plasma: 28,444 (4,957-67,051) vs 2,966.5 (2,167-5,025) copies of amplifiable DNA per mL, P < .01. Median of 5 mL (interquartile range, 4.5-5) of pleural fluid supernatant was adequate for cfDNA testing. INTERPRETATION: The diagnostic yield of pleural cfDNA NGS for oncogenic mutations in lung adenocarcinoma patients is comparable to tumor biopsies and higher than pleural cytology and plasma cfDNA. The pleural cfDNA can be longitudinally collected, can be readily incorporated in clinical workflow, and may decrease the need for additional biopsies.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Mahmood K, Jampani P, Clarke JM, et al. High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma. Chest. 2023. PMID: 36693563. doi:10.1016/j.chest.2023.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。